Bellevue Group Ag Eagle Pharmaceuticals, Inc. Transaction History

Bellevue Group Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 12, 2019	SELL	$36.72 - $67.73 $660,960 - $1.22 Million	-18,000 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$66.65 - $83.86 $999,750 - $1.26 Million	-15,000 Reduced 45.45%	18,000 $1.25 Million
Q4 2017 Feb 14, 2018	SELL	$49.6 - $60.87 $2.41 Million - $2.96 Million	-48,550 Reduced 59.53%	33,000 $1.76 Million
Q3 2017 Nov 13, 2017	SELL	$46.62 - $60.36 $2.35 Million - $3.04 Million	-50,440 Reduced 38.22%	81,550 $4.86 Million
Q2 2017 Aug 14, 2017	BUY	N/A	131,990	131,990 $10.4 Million

8.59M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $12.5M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.